31 results about "Intestine injury" patented technology

The invention belongs to the field of medical technology, and relates to application of valeric acid in the preparation of medicine for preventing and / or curing tumor radiotherapy side reactions. Researches find that valeric acid can obviously improve intestinal injury, caused by partial irradiation on abdomen of gamma ray, of a mouse, so that the survival rate of the laboratory mouse is obviouslyincreased, the weight is expected to be increased, the level of intestinal inflammation is obviously reduced; and no paradoxical reaction appears on the laboratory mouse, so that valeric acid can beeffectively used for preventing and / or curing tumor radiotherapy side reactions, and the toxic and / or side effects are relatively low.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

The disclosure provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stern Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. More specifically, the disclosure provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.

The invention discloses a lactobacillus rhamnosus (Lactobacillus rhamnosus FLRH93), which is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 60956. The results of injury intervention experiments in animals showed that Lactobacillus rhamnosus FLRH93 can significantly improve the intestinal injury caused by drugs. Histological stained sections showed that the strain maintained the structural integrity of the small intestine, reduced the loss of goblet cells after drug treatment, and It can regulate the secretion of Bcl‑2 and NLRP3, thereby reducing the production of inflammatory factors IL1‑β and TNF‑α. The invention belongs to the technical field of microbes, and the bacterial strain provided can improve the survival rate of drug-injured mice, and can also significantly promote the healing of wounded skin.

The invention discloses a preparation for preventing and treating black body color missing symptoms of pelteobagrus fulvidracos due to poor feed freshness. The preparation is prepared from the following methods that the traditional Chinese medicine raw materials including herba ecliptae, ficus carica, cortex moutan, flastem milkvetch seeds and fructus cnidii are used; A, medicine juice decoction is performed: the herba ecliptae, the ficus carica, the cortex moutan, the flastem milkvetch seeds and the fructus cnidii are added into water for decoction; medicine juice is filtered and taken; then, chlorpheniramine maleate is added into the medicine juice; the medicine juice is concentrated to obtain a mixed solution A; B, coating is performed: the mixed solution A is coated to obtain the preparation for preventing and treating black body color missing symptoms of the pelteobagrus fulvidracos due to poor feed freshness. The preparation can be used for effectively preventing and treating the black body color missing occurring symptoms of the pelteobagrus fulvidracos due to fish meal staleness in feed, and also achieves a better repairing effect on stomach and intestine injury due to fish meal staleness. Therefore wide application prospects are realized.

The invention belongs to the technical field of radiation medicine, and specifically relates to a method for building a mouse acute radiation duodenitis model. According to the method, 8Gy gamma-ray irradiation is performed on mice, the irradiation part is the abdomen, duodenitis pathological analysis is performed on the mice after two weeks since the irradiation is conducted, and the protein expression levels of an apoptosis related factor BCL-2 and an inflammation related factor TGF-beta1 are detected. According to the invention, an irradiation method which is closer to clinical radiotherapyis adopted to build the radiation duodenitis model, thereby providing an experimental basis for prevention and treatment research for clinical radiation intestinal injuries.

A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceutically acceptable salt thereof:to an expectant human mother suffering from antenatal fetal inflammation. The method prevents or reduces the risk of organ damages, including brain, lung and intestinal damages, and sequelae therefrom, in the neonates, as well as the risk of neonatal death.

The invention belongs to the technical field of medicine, and relates to application of indolepopionic acid to preparation of drugs for preventing and / or treating tumor radiotherapy side effect. Through research, the fact that indolepopionic acid can obviously improve intestinal injury of mice, caused by gama ray irradiation, is found, the improvement shows that the survival rate of laboratory mice is obviously improved, the weight is risen again, the intestinal inflammation level is obviously reduced, and paradoxical reaction of the laboratory mice does not occur, the fact that indolepopionicacid can be effectively applied to the prevention and / or treatment of tumor radiotherapy side effect is shown, and the indolepopionic acid is low in toxic and side effect, and effective before and after being taken, and has a wide application potential.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

The present invention provides compositions and methods for preventing or treating gastrointestinal injury induced by chemotherapy or radiotherapy.

The invention belongs to the field of biology, and relates to the application of serum ssc-miR-194b as a molecular marker for detecting intestinal stress damage in piglets. The nucleotide sequence of serum ssc-miR-194b is shown in SEQ ID NO.1, reversed The nucleotide sequence of the stem-loop primer required to record ssc-miR-194b is shown in SEQ ID NO.2, and the nucleotide sequence of the forward primer required to amplify ssc-miR-194b is shown in SEQ ID NO. As shown in 3, the above primers can be used to diagnose the intestinal stress injury of weaned piglets. The diagnostic method includes the extraction of serum total RNA, the isolation of small molecule RNA, cDNA synthesis, PCR amplification and identification. It provides guidance for the prevention, diagnosis and treatment of tract stress injury, and provides a new molecular marker for marker-assisted selection of pig stress-resistant strains.

The invention provides for methods of delivering heparin binding epidermal growth factor (HB-EGF) to sites of intestinal injury using stem cell derived exosomes. In particular, the invention provides for methods of delivering HB-EGF loaded stem cell-derived exosomes to sites of intestinal injury and methods of protecting a subject and method of treating intestinal injury, such as necrotizing enterocolitis (NEC).